A Business Model  that  Sustains Enterprise Value Astellas’ ultimate aim is to translate innovation into value for patients. W will concentrate our resources on ethical  pharmaceuticals, particularly in the innovative drug business, and our efforts in resear ch and development (R&D) will be unwavering. Astellas champions a Global Category Leader (GCL) business model, based on which we establish a com - petitive edge by creating innovative pharmaceutical products in multiple therapeutic ar eas with a high level of unmet  medical needs and deliver them to patients all over the world. We have alr eady established our position as a GCL in urology and transplantation, and we are now focusing our efforts on oncology as a thir d field. 6 Astellas Pharma Inc.  _ Annual Report 2014 G lobal  C ategory  L eader Provide innovative pharmaceutical products to the world Establish competitive edge as a leader Multiple therapeutic areas with a high level  of unmet medical needs Concentrate  management  resources Innovative drug  business Curr ent GCL ar eas Focus on innovative drug business Astellas’ own distribution channels in over 50 countries Superior R&D capabilities Robust sales and marketing platform in Japan Our Strengths Urology T ransplantation